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This prospective long-term cohort study investigated
the incidence of malignancies in severe psoriasis pa-
tients treated with cyclosporine. A total of 1252 patients
were followed prospectively for up to 5 y. Malignancies
were recorded prospectively. Incidence rates for malig-
nancies were compared with the general population
using standardized incidence ratios. The e¡ect of dura-
tion of exposure to cyclosporine and to previously ad-
ministered anti-psoriatic treatments on the incidence
of malignancies was investigated using Poisson regres-
sion models. The mean age of patients was 43 y and on
average, patients received cyclosporine for 1.9 y. Malig-
nancies were diagnosed in 47 patients (3.8%), 49% of
them had skin malignancies. The standardized inci-
dence ratio in the study cohort was 2.1 as compared
with the general population. The higher incidence of
malignancies was attributed to a 6-fold higher inci-
dence of skin malignancies, most of which were squa-
mous cell carcinoma. The incidence of nonskin
malignancy overall was not signi¢cantly higher in this
study than in the general population. Duration of expo-
sure to cyclosporine, exposure to psoralen and ultravio-
let A, exposure to methotrexate, and exposure to
immunosuppressants showed a signi¢cant e¡ect on the
incidence of nonmelanoma skin malignancies. In con-
clusion, treatment of psoriasis with cyclosporine is asso-
ciated with an increased risk of nonmelanoma skin
cancer. Patients treated for more than 2 y with cyclos-
porine were shown to have a higher risk. In addition,
exposure to psoralen and ultraviolet A and to other
immunosuppressants was shown to contribute to the
overall risk. Key words: autoimmune diseases/immuno-
suppressant/skin cancer/standardized incidence ratio. J Invest
Dermatol 120:211 ^216, 2003
S
evere psoriasis can seriously a¡ect a patient’s quality of
life (Finlay and Coles, 1995) and life-long intermittent
treatment with systemic therapies may often be required
to control the disease (Spuls et al, 1997). Systemic thera-
pies, however, can induce adverse e¡ects that restrict
their long-term use. For example psoralen and ultraviolet (UV)
A (PUVA) therapy has been associated with an increased risk of
skin cancer (Stern et al, 1984, 1997a; Lindel˛f et al, 1991). Hepato-
toxicity is a major limitation to long-term methotrexate use
(Roenigk et al, 1998). Similarly, synthetic retinoids are highly ter-
atogenic and are often ine¡ective as a monotherapy (Paul and
Dubertret, 1998) and long-term treatment with cyclosporine is as-
sociated with nephrotoxicity (Grossman et al, 1996). In addition,
long-term use of immunosuppressants such as cyclosporine is as-
sociated with a potential safety concern because an increased risk
of malignancy, primarily of the skin and lymphoid tissue is ob-
served in transplant patients treated with immunosuppressants re-
gimens (Sloan et al, 1977; Cockburn and Krupp, 1989; Penn, 1994;
Jonas et al, 1997). The risk appears to be less in patients treated
with cyclosporine for autoimmune diseases (Van den Borne et al,
1998; Paul and Hornig, 1999).With the exception of PUVA ther-
apy, there are scant data available on the long-term safety of sys-
temic treatment in psoriasis. The carcinogenic risk is a concern
relevant to the psoriasis population as the majority of patients
with severe psoriasis may receive various carcinogenic treatments,
including arsenic preparations, tar, ionizing radiation, photother-
apy, and PUVA. Furthermore, several epidemiologic studies have
shown that psoriasis patients have already an increased risk of
malignancies primarily of the skin (Frentz and Olsen, 1999;
Hannuksela-Svahn et al, 2000; Margolis et al, 2001). Consequently,
there is a need to evaluate the risk of malignancies in psoriasis
patients receiving cyclosporine and to identify the possible role
of other risk factors in the development of malignancy. The pri-
mary objective of the present prospective cohort study was to in-
vestigate the type and incidence of malignancies that may occur
in patients treated with cyclosporine for psoriasis and to identify
the contributing role of duration of exposure and of other psor-
iasis treatments.
SUBJECTS ANDMETHODS
This study was designed as an open, uncontrolled, nonrandomized, multi-
center, prospective observational cohort study. It was conducted in 277
centers in 11 countries: Austria, Canada, Denmark, France, Germany, Great
Britain, Italy, Portugal, Spain, Switzerland, and Turkey.
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Patients with severe psoriasis treated with cyclosporine (as indicated in
the product monograph) were included in the study. All patients were in-
cluded in the study if they had received at least 1 mo of cyclosporine treat-
ment and had to be followed-up for 5 y.The evaluation schedule included a
baseline clinical assessment and follow-up clinical assessments at month 1,
and every 6 mo thereafter until month 60. All assessments had to be per-
formed by a dermatologist. Malignancies were monitored continuously
and were recorded on a dedicated form. Data on all malignancies were ver-
i¢ed by direct contact with the investigators.
Other safety assessments consisted of information on cyclosporine dose
and duration of therapy, information on concomitant therapy received for
psoriasis in addition to regular measurements of serum creatinine, blood
pressure, and weight.
Statistical analysis All analyses were performed on the safety
population, which consists of all patients who received at least one dose of
cyclosporine. Incidence rate of malignancies and corresponding 95%
con¢dence intervals (CI) were calculated separately for each year of
follow-up and overall. Separate incidence rates were calculated for periods
of low and high exposure to cyclosporine de¢ned as at most 2 y and more
than 2 y of cumulative treatment. For each type of malignancy, the
incidence observed in the cohort was compared with the corresponding
incidence in the general population using standardized incidence ratios
(SIR), which represent the ratio between observed and expected number
of malignancies.
The expected number of malignancies was calculated by applying the
incidence rate of the general population to the study cohort. Incidence
rates in the general population were taken from national or regional
cancer registries in the countries participating in the study (Parkin et al,
1992, 1997). Attention was paid to select as reference registries including
both basal cell carcinoma (BCC) and squamous cell carcinoma (SCC).
Separate incidence rates for BCC and SCC were not provided in the
registries. No registry was available for Portugal and Turkey.
Consequently, registries for Spain (Zaragoza) and Italy (Modena) were
chosen as respective references for these two countries. Strata were formed
by the cross-sections of age group, sex, and country. For each patient,
follow-up years were allocated to age groups based on the patient’s age at
the midpoint of the follow-up year. In addition, separate SIR were
calculated for follow-up years with low and high exposure to
cyclosporine. The in£uence of history of malignancy and of previous
use of other psoriasis treatment (methotrexate, PUVA, retinoids,
immunosuppressants, phototherapy, tar) was investigated. The e¡ect of
exposure to cyclosporine and to any of the explanatory variables listed
above was investigated using Poisson regression models for the SIR,
incorporating the expected number of malignancies as prior weights in
the model to account for overdispersion (Breslow and Day, 1988). All
models included three explanatory variables: exposure to cyclosporine,
previous history of malignancy, and the respective exposure to previous
treatments for psoriasis (PUVA, oral retinoids, methotrexate, other
immuno-suppressants, phototherapy, tar). The signi¢cance of each e¡ect
was determined using a likelihood ratio test. Relative risks were presented
together with 95% CI.
The Poisson regression was performed for all malignancies, all skin
malignancies, all nonmelanoma skin malignancies, all nonskin mali-
gnancies, and for BCC and SCC. Other individual types of malignancies
were not further analyzed because of the low number of events.
In the analyses of BCC and SCC, it was assumed that the proportion of
BCC among nonmelanoma skin cancer in the general population is 80%
for men and 86% for women. Accordingly the proportion of SCC was
estimated to be 20% for men and 14% for women. These estimates are
based on literature data from European countries and Canada, which
showed consistent proportions of BCC and SCC across countries (Stern,
1999; Holme et al, 2000).
RESULTS
Patient disposition and follow-up A total of 1252 patients
were included in the safety population. The median duration of
follow-up was 4.5 y (range 0^8.6 y) with 48% of patients having
attended the month 60 ¢nal visit. The total cohort was 4440
person-years of follow-up.
Baseline demographics and background disease chara-
cteristics (Table I) The study population had an age range
from 9 to 88 y with an average age of 43 y. Sixty-eight percent
of the patients were male and 95% of the patients were aged
between 20 and 75 y. On average, patients had su¡ered from
psoriasis for 16 y and the mean age at onset of psoriasis was 27 y.
A total of 7% of patients su¡ered from psoriatic arthropathy. The
most commonly used prior therapies for psoriasis were PUVA
(47%), retinoids (45%), methotrexate (28%), phototherapy (19%),
tar (8%), cyclosporine (8%), and other immunosuppressants
(6%). There was no noteworthy di¡erence in the demographic
characteristics observed between the patient group that received
more than 2 y of cyclosporine (high exposure group) and the
patient group that received less than 2 y (low exposure group)
during the study. The proportion of patients previously exposed
to PUVA, retinoids, and methotrexate was slightly higher in the
high cyclosporine exposure group as compared with the low
exposure group (Table I).
Exposure to cyclosporine and other systemic psoriasis
treatments The mean daily starting dose of cyclosporine was 3
mg per kg, starting doses higher than 3.5 mg per kg were taken
by 20% of patients. Thereafter, the mean daily dose decreased
over time from 3.1 mg per kg at month 6 to 2.7 mg per kg at
the end of month 54. At each time point, between 18 and 28%
of patients received daily doses between 3.5 mg per kg and 5 mg
per kg. Doses of more than 5 mg per kg were taken by 3^4% of
patients. Approximately 40% of all patients received cyclosporine
intermittently, whereas the remaining 60% received it conti-
nuously until they ceased cyclosporine treatment permanently.
The mean duration of cyclosporine therapy was 1.9 y with 471
(38%) patients receiving it for more than 2 y and 201 patients
(16%) receiving it for more than 4 y. During the follow-up
period, 34% of patients received other systemic therapy for
psoriasis. These consisted primarily of methotrexate and
retinoids, which were received by 20% of patients. PUVA and
Table I. Baseline characteristics of the patients
Total
(n¼1252)
Patients with at most
2 y of cyclosporine
(n¼ 781)
Patients with more than
2 y of cyclosporine
(n¼ 471)
Age (y)
Mean7SD 43.3714.0 44.0714.3 42.3713.4
Range 9^88 9^88 11^80
Sex 68/32 70/30 65/35
(% male/female)
Weight (kg)
Mean7SD 76.9716.6 76.7716.4 77.3716.9
Range 26^174 26^174 30^147
Duration of psoriasis (y)
Mean7SD 16.2711.2 15.8711.5 16.8710.7
Age at onset of psoriasis (y)
Mean7SD 27.1714.3 28.2714.6 25.3713.6
Previous systemic therapy of psoriasis (% of patients receiving therapy)
PUVA 47 45 49
Retinoids 45 41 51
MTX 28 25 33
UVB/UVA 19 21 17
Tar 8 9 8
Cyclosporine 8 8 8
Immuno. 6 4 8
Fumaric a. 2 2 1
Arsenic o 1 o 1 o 1
Ioniz. rad. o 1 o 1 o 1
MTX, methotrexate; ioniz. rad., ionizing radiation; immuno., immunosuppres-
sant w/o cyclosporine; fumaric a., fumaric acid.
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phototherapy were received by 13% and 10% of patients,
respectively.
Incidence of malignancies and distribution across the
follow-up period Malignancies were diagnosed in 47 patients
(3.8%). The corresponding yearly incidence density rate was 10.8
per 1000 person-years of follow-up. Forty-nine percent of the
malignancies were skin cancers. The number and percentage of
patients with the most frequent malignancies and corresponding
incidence-density rates are displayed inTable II. The proportion
of SCC to BCCwas 3 : 1. All patients with BCC and/or SCC had
previously received PUVA therapy. The yearly incidence density
rate of malignancies was equally distributed across years of
follow-up and ranged from 10.2 to 12.5 per 1000 person-years for
follow-up years 1^5. There was no trend towards an increased
incidence of malignancies over time within the cohort. In 30 of
the 47 patients (64%) malignancies occurred while patients were
on cyclosporine. The mean duration of cyclosporine treatment at
the time the ¢rst malignancy was diagnosed was 22 mo (range
0.4^55 mo). In the remaining 17 patients (36%) malignancies
were diagnosed after cyclosporine had been stopped, which on
average was 19.6 mo after last administration.
Comparison of the incidence of malignancies with the
general population and e¡ect of duration of exposure to
cyclosporine Table III shows the SIR and 95% CI by
malignancy and exposure to cyclosporine. The overall incidence
of malignancies was signi¢cantly higher in the cohort as
compared with the general population. The 2-fold higher
incidence of malignancy was mainly caused by a 6-fold higher
incidence of skin malignancies most of which were
nonmelanoma skin cancers. The incidence of nonmelanoma skin
cancer was higher during high-exposure follow-up years, which
is re£ected in the increased value of the high-exposure SIR
compared with the low-exposure SIR. The increase in the
incidence of nonmelanoma skin cancer was mainly driven by a
24.6-fold increase in the incidence of SCC in the cohort.
The incidence of nonskin malignancies was not signi¢cantly
increased as compared with the general population (SIR: 1.3;
95% CI: 0.8^1.9). Among nonskin malignancies, only the
SIR for leukemia was signi¢cantly elevated in the cohort (SIR:
7.3; 95% CI: 1.5^21.5). CI were generally large, however, due to
a low observed number of events of individual types of nonskin
malignancies (Table III).
E¡ect of exposure to other systemic psoriasis treatments on
the incidence of malignancies Estimated relative risks for
each factor, adjusted for the other factors in the model are
presented together with 95% CI in Table IV. The duration of
exposure to cyclosporine showed a signi¢cant e¡ect on the
incidence of malignancies of any type, on the incidence of skin
malignancies, and on the incidence of nonmelanoma skin
malignancies, whereas no signi¢cant increased risk of nonskin
malignancies was observed. The relative risk was 3.3 for
nonmelanoma skin malignancies (95% CI 1.3^8.4) and 1.5 for
nonskin malignancies (95% CI 0.6^3.5).
Aside from exposure to cyclosporine, the following factors
showed a signi¢cant e¡ect on the incidence of malignancies of
any type. Previous exposure to PUVA (relative risk 3.5; 95% CI:
1.8^7.2), previous exposure to retinoids (relative risk 2.9; 95% CI:
1.5^6.3) and previous exposure to immunosuppressants (relative
risk 2.0; 95% CI: 1.0^3.7) signi¢cantly increased the risk of
malignancies. Similarly these e¡ects were mainly driven by
a higher risk of developing skin malignancies, especially
nonmelanoma skin malignancies, as compared with the general
population. The highest increase in the risk of skin malignancies
Table II. Number (%) of patients with malignancies by
selected category of malignancy, and corresponding
incidence density rates with 95% CI
Per 1000 person-years
Patients Person- Incidence
N (%) Yearsb rate 95% CI
Any malignancy 47 3.8 4340 10.8 8.0^14.4
Skin malignancies 23 1.8 4377 5.3 3.3^7.9
BCC 5 0.4 4426 1.1 0.4^2.6
SCC 15 1.2 4401 3.4 1.9^5.6
Melanoma 2 0.2 4431 0.5 0.1^1.6
Porocarcinoma 1 0.1 4439 0.2 0.0^1.3
Nonskin malignanciesa 24 1.9 4404 5.4 3.5^8.1
Colon cancer 3 0.2 4435 0.7 0.1^2.0
Leukemia 3 0.2 4440 0.7 0.1^2.0
Lymphoma 2 0.2 4437 0.5 0.1^1.6
Lung cancer 2 0.2 4439 0.5 0.1^1.6
Esophageal cancer 2 0.2 4434 0.5 0.1^1.6
Breast cancer 2 0.2 4437 0.5 0.1^1.6
Gastric cancer 2 0.2 4435 0.5 0.1^1.6
aAlso including malignancies experienced by one patient only, these are not dis-
played separately in this table
bNumbers are di¡erent because patients are censored at the time they experience
a malignancy.
Table III. SIR and 95% CIb by malignancy and exposure to cyclosporine
Overall Low exposure High exposure
Person-yearsa SIR 95% CI Person-years SIR 95% CI Person-years SIR 95% CI
Any malignancy 4294 2.1 1.6^2.9 3280 1.8 1.2^2.6 1014 3.3 1.9^5.3
Any skin malignancy 4330 6.1 3.8^9.1 3300 4.8 2.6^8.1 1029 10.1 4.6^19.2
Nonmelanoma skin malignancy 4339 6.2 3.8^9.5 3310 4.6 2.4^8.1 1029 11.4 5.2^21.7
BCC 4379 1.8 0.6^4.1 3338 0.9 0.1^3.3 1041 4.6 0.9^13.3
SCC 4354 24.6 13.8^40.7 3317 19.2 8.8^36.5 1037 42.7 15.7^93.2
Malignant melanoma 4384 4.7 0.6^17.0 3336 6.2 0.8^22.5 1048 0.0
Any nonskin malignancy 4357 1.3 0.8^1.9 3324 1.2 0.7^1.9 1033 1.7 0.7^3.5
Lymphoma 4390 2.0 0.2^7.2 3342 1.3 0.0^7.2 1048 4.3 0.1^23.9
Lung cancer 4393 0.6 0.1^2.2 3344 0.8 0.1^2.8 1048 0.0
Esophageal cancer 4387 5.1 0.6^18.4 3342 6.7 0.8^24.1 1045 0.0
Leukemia 4393 7.3 1.5^21.5 3345 9.5 2.0^27.7 1048 0.0
Colon cancer 4388 2.1 0.4^6.1 3343 0.9 0.0^5.0 1045 6.3 0.8^22.8
Breast cancer 4390 1.2 0.1^4.2 3345 0.0 1045 4.2 0.5^15.2
Gastric cancer 4388 2.1 0.3^7.5 3340 1.3 0.0^7.3 1048 5.1 0.1^28.6
aPerson-years of follow-up;
b95% CI for SIR
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was obtained with PUVA exposure. Exposure to PUVA was
estimated to increase the risk of nonmelanoma skin cancer by
factor 7.3 (95% CI 1.3^134.5). Exposure to methotrexate,
immunosuppressants as well as high vs low exposure to
cyclosporine were also signi¢cant risk factors for nonmelanoma
skin cancers in the cohort. Exposure to tar, phototherapy alone,
and retinoids showed no signi¢cant e¡ect. The results of the
separate analyses for SCC and BCC were consistent with the
results of the analysis of nonmelanoma skin cancer, although
the CI were larger due to low number of events. With regard
to nonskin malignancies, the only signi¢cant factor in the
multivariate Poisson regression model was previous exposure to
PUVA (relative risk: 2.5; 95% CI: 1.1^6.5).
DISCUSSION
The analysis of the cyclosporine long-term cohort study provides
important information on the long-term safety of cyclosporine in
the treatment of psoriasis. The total cohort was almost 4500 per-
son-years of follow-up. This represents to our knowledge the lar-
gest prospective cohort of psoriatic patients after the PUVA
cohort study from the U.S.A. (Stern et al, 1984). The majority
of patients had previously received UV therapy for psoriasis
(including UVB, PUVA, or combination therapy) or systemic
therapy, including methotrexate, other immunosuppressants, or
retinoids. Indirectly, this re£ects the nature of the population re-
ceiving cyclosporine treatment as consisting of patients with se-
vere psoriasis. The overall incidence of malignancies was about
twice as high in this cohort of patients with severe psoriasis than
in the general population. The higher incidence of malignancies
of any type in the cohort was mainly caused by a 6-fold higher
incidence of skin malignancies, mostly nonmelanoma skin ma-
lignancies. Nonskin malignancies overall were not signi¢cantly
more frequent in this cohort than in the general population. A
signi¢cantly higher incidence of leukemia was observed in the
cohort as compared with the general population. Three patients
developed leukemia after a relatively short exposure to cyclospor-
ine and with no apparent relationship to the duration of expo-
sure. Given the small size of the cohort and the absence of
relationship to exposure, the results should be interpreted with
caution and further studies are needed to con¢rm these ¢ndings.
The SIR for lymphoma is 2 with a wide CI. This SIR is similar
to the one observed in a cohort of patients with moderate to se-
vere psoriasis reported before the introduction of cyclosporine
(Hannuksela-Svahn et al, 2000).
There are many factors in£uencing the risk of malignancies in
severe psoriasis patients (Murphy, 1999). The contributing role of
PUVA, cyclosporine, and methotrexate to the increased risk of
skin cancer in the psoriasis population has been demonstrated,
although few studies have assessed simultaneously the respective
contribution of individual psoriasis therapies (Stern et al, 1984;
Lindel˛f et al, 1999; Hannuksela-Svahn et al, 2000; Marcil and
Stern, 2001).
In this study, previous history of malignancy, high exposure to
cyclosporine, and previous exposure to PUVA, methotrexate, and
immunosuppressants were associated with an increased risk of
nonmelanoma skin malignancies. The contribution of the role
of retinoids that were identi¢ed as being a signi¢cant risk factor
for malignancies overall and skin malignancies should be inter-
preted with caution because of possible confounding. Retinoids
are frequently used in combination with PUVA and it may be
di⁄cult to separate the individual contribution of retinoids in
the model. Moreover, use of retinoids has been advocated in pa-
tients experiencing SCC to prevent recurrence suggesting a pos-
sible confounding by indication when assessing risk of skin
cancer in patients treated with retinoids (Hannuksela-Svahn et al,
2000).
One limitation of this study is that the incidence of malignan-
cies had to be compared with the general population. This
is a common limitation of most cohort studies investigating
the risk of malignancies in psoriasis patients (Stern et al, 1984;
Lindel˛f et al, 1991; Frentz and Olsen, 1999a,b; Hannuksela-Svahn
et al, 2000). Problems may arise from di¡erent sources. First,
psoriasis per se is associated with an increased risk of malignancies.
An increased risk of nonskin malignancies has been observed
in psoriasis in some studies, but no consistent pattern was found
across studies (Stern et al, 1997b; Frentz and Olsen, 1999a,b;
Hannuksela-Svahn et al, 2000; Margolis et al, 2001). Secondly,
skin cancers are more likely to be detected and reported in
Table IV. Adjusted relative risks and 95% CI
95% CI
All malignancies
Exposure to cyclosporine (high/low) 2.0 1.1^3.8
Exposure to PUVA (some/none) 3.5 1.8^7.2
Exposure to retinoids (some/none) 2.9 1.5^6.3
Exposure to methotrexate (some/none) 1.8 1.0^3.2a
Exposure to immunosuppressant (some/none) 2.0 1.0^3.7
Exposure to phototherapy (some/none) 1.2 0.6^2.3
Exposure to tar (some/none) 2.1 0.9^4.5
All skin malignancies
Exposure to cyclosporine (high/low) 2.7 1.1^6.4
Exposure to PUVA (some/none) 5.8 2.0^25.0
Exposure to retinoids (some/none) 4.5 1.5^19.5
Exposure to methotrexate (some/none) 2.1 0.9^5.3
Exposure to immunosuppressant (some/none) 2.9 1.2^6.8
Exposure to phototherapy (some/none) 0.7 0.2^1.8
Exposure to tar (some/none) 2.4 0.7^6.6
All nonmelanoma skin malignancies
Exposure to cyclosporine (high/low) 3.3 1.3^8.4
Exposure to PUVA (some/none) 7.3 1.3^134.5
Exposure to retinoids (some/none) 4.6 0.9^86.1
Exposure to methotrexate (some/none) 2.7 1.1^7.3
Exposure to immunosuppressant (some/none) 3.5 1.4^8.4
Exposure to phototherapy (some/none) 0.5 0.1^1.5
Exposure to tar (some/none) 1.9 0.4^5.7
All BCC
Exposure to cyclosporine (high/low) 4.9 0.8^36.9
Exposure to PUVA (some/none) Not
estimable
Exposure to retinoids (some/none) Not
estimable
Exposure to methotrexate (some/none) 2.5 0.4^18.7
Exposure to immunosuppressant (some/none) 3.3 0.4^19.6
Exposure to phototherapy (some/none) 2.3 0.1^24.0
Exposure to tar (some/none) 6.5 0.9^39.4
All SCC
Exposure to cyclosporine (high/low) 3.3 1.0^10.6b
Exposure to PUVA (some/none) 4.4 0.7^84.7
Exposure to retinoids (some/none) 2.6 0.4^50.7
Exposure to methotrexate (some/none) 2.5 0.8^8.6
Exposure to immunosuppressant (some/none) 4.0 1.3^11.5
Exposure to phototherapy (some/none) 0.6 0.1^2.7
Exposure to tar (some/none) 1.5 0.1^9.3
All nonskin malignancies
Exposure to cyclosporine (high/low) 1.5 0.6^3.5
Exposure to PUVA (some/none) 2.5 1.1^6.5
Exposure to retinoids (some/none) 2.1 0.9^5.4
Exposure to methotrexate (some/none) 1.3 0.6^3.1
Exposure to immunosuppressant (some/none) 1.3 0.4^3.2
Exposure to phototherapy (some/none) 1.6 0.6^3.8
Exposure to tar (some/none) 1.5 0.4^4.5
Results of Poisson regressions with SIR as outcome variable and previous his-
tory of malignancy, exposure to cyclosporine, and exposure to respective previous
therapy as explanatory variables.
aCI includes 1.0.
bCI does not include 1.0.
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patients followed up by dermatologists. This detection bias
may have produced an overestimation of the risk of skin cancer
in the cohort. Thirdly, perfect matching between the study
population and cancer registries is not possible because cancer
registries do not exist in all countries. This is relevant to this
study, which includes patients from a very large geographic back-
ground.
It is noteworthy that the risks estimated from this study are
very close to those of a recent study in severe psoriasis patients
from an administrative database (Margolis et al, 2001). In this
study, the relative risk for all malignancies in patients with severe
psoriasis was 1.78 and the risk of nonmelanoma skin cancer was
4.15 as compared with 2.1 and 6.1 in the present cohort. The risk
of nonmelanoma skin malignancies observed in this study is also
close to the one observed in cohorts of severe psoriasis patients
from northern Europe showing relative risk of nonmelanoma
skin cancers varying from 2.6 to 4.83 (Frentz and Olsen, 1999a,b;
Hannuksela-Svahn et al, 1999). High exposure to cyclosporine as
de¢ned by more than 2 y of treatment was estimated to increase
the risk of nonmelanoma skin cancer by a factor of 3.3 compared
with low exposure. Among previous therapies, the most impor-
tant factor in£uencing the risk of nonmelanoma skin cancer
was found to be PUVA with a relative risk of 7.3. Among the
21 patients who developed nonmelanoma skin cancer 20 (95%)
had previously received PUVA. This is in line with the results
of a recent meta-analysis that indicated PUVA is the major skin
carcinogen in psoriasis patients; high exposure being asso-
ciated with a 14-fold higher incidence of SCC (Stern and Lunder,
1998).
As in other studies, it might have been interesting to analyze
the e¡ect of cyclosporine dose instead of the duration of treat-
ment as risk factor. Signi¢cant e¡ect of the dose of cyclosporine
on the incidence of skin malignancies was shown in a cohort
study in transplantation (Dantal et al, 1998). Such an analysis was
not performed, however, as the use of cyclosporine in psoriasis is
associated with frequent changes in doses of study medication for
each patient depending upon the clinical outcome. In addition,
many psoriasis patients receive intermittent treatment with cy-
closporine as opposed to transplant patients who receive it
continuously (Berth-Jones et al, 1997; Ho et al, 1999, 2001). Long-
term studies in transplantation have shown that duration of expo-
sure to immunosuppressants is an important factor in£uencing
the risk of malignancies (Sheil, 2001).Therefore duration of expo-
sure was chosen as the relevant parameter for categorization of
exposure in the study population. Similarly, it would have been
useful to have more detailed information on previous exposure to
other anti-psoriatic drugs, such as duration and dose, as it is com-
mon practice to rotate treatment in psoriasis. In a study of this
size and duration, however, it was decided to take a pragmatic
approach and not record such data as such details are known to
be highly variable in the individual patient. Lastly the duration
of follow-up in the cohort is relatively limited and does not allow
a precise estimate of incidence rates of individual types of
nonskin cancers. Studies with longer follow-up, including
larger groups of patients will be required to assess more precisely
the e¡ect of cyclosporine treatment on the risk of nonskin
malignancies.
In conclusion, the risk of malignancy associated with cyclos-
porine treatment in psoriasis appears to be signi¢cantly increased
with more than 2 y of cumulative treatment as compared with
less than 2 y. This is mainly due to an increase in risk of nonme-
lanoma skin cancers, mostly SCC. The contributing role of
previous exposure to PUVA, methotrexate, and other immuno-
suppressants was demonstrated. The incidence of nonskin cancer
does not appear to be signi¢cantly increased overall. For indivi-
dual types of nonskin malignancies, however, the cohort
is not large enough to provide a precise estimate of incidence.
The increased incidence of nonmelanoma skin cancers in the co-
hort is in line with published literature in psoriasis patients,
which thus provides con¢dence with regard to the validity of
the results.
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